Status:
COMPLETED
IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
CancerCare Manitoba
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Brief Summary
Glioblastomas (GBM) are the most common primary malignant brain tumor with a very high recurrence rate and an average survival of 14 months. Identifying an imaging biomarker to predict recurrence is c...
Detailed Description
Glioblastomas (GBM) are the most common type of primary malignant brain tumor with a very high rate of recurrence. The average survival of patients with GBM is 14 months, and the 5-year survival rate ...
Eligibility Criteria
Inclusion
- At least 18 years old
- Patients with suspected GBM on initial MRI of brain
- MRI scans with isolated restricted diffusion foci noted
Exclusion
- Participants who are pregnant
- Known contraindication to MRI contrast agent, e.g., allergy or anaphylactic reaction
- Known end-stage renal disease
Key Trial Info
Start Date :
October 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2023
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT05402241
Start Date
October 21 2021
End Date
November 15 2023
Last Update
May 23 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Manitoba
Winnipeg, Manitoba, Canada, R3E 3P5
2
Health Sciences Centre
Winnipeg MB, Manitoba, Canada, R3A 1R9